Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

FTSE slides after BOE meeting as pound pops higher

share with twitter share with LinkedIn share with facebook
share via e-mail
02/08/2018 | 06:08pm CEST
A worker shelters from the rain as he passes the London Stock Exchange in London

MILAN/LONDON (Reuters) - The UK's top share index fell on Thursday after the Bank of England raised the prospect of higher interest rates, sending the pound higher which weighed on big British overseas earners.

The FTSE <.FTSE> was closed 1.5 percent lower at 7,170.69 points. The index is down 6.7 percent in the year to date, making it the worst performer among top European bourses.

The Bank of England said that interest rates probably need to rise sooner and by a bit more than it thought only three months ago, which boosted sterling.

The rise in the currency weighed on the FTSE's predominantly dollar-earning firms, with shares in heavyweight consumer staples British American Tobacco (>> British American Tobacco), Reckitt Benckiser (>> Reckitt Benckiser) and Unilever (>> Unilever) dropping 1.8 percent to 3.2 percent.

"We are growing cautious on those companies which rely heavily on overseas earnings, as rising interest rates could cause the pound to strengthen further from here," Andrew Morgan, portfolio manager of Alpha:r² at Walker Crips, said.

"We continue to be relatively defensively positioned in equities, despite the recent dip, and are looking at certain sectors - such as Financials - which tend to benefit from a rising interest rate environment," Morgan added.

On the day shares in banking stocks RBS (>> Royal Bank of Scotland Group), Barclays (>> Barclays) and Lloyds (>> Lloyds Banking Group) were among the dozen or so stocks in positive territory, up 0.4 percent to 1 percent.

GlaxoSmithKline (>> GlaxoSmithKline) was another riser, up 1.4 percent after U.S. regulators delayed approval of a generic copy from Novartis of its blockbuster Advair lung drug and after the group took legal action against Gilead Sciences (>> Gilead Sciences) over a new HIV drug.

The news helped build confidence after an upbeat results presentation by GlaxoSmithKline on Wednesday. Competitive threats to its respiratory and HIV businesses are seen as key risks for the company's stock.

AstraZeneca (>> AstraZeneca) rose 1.2 percent, boosted by a price target upgrade from Berenberg.

WPP (>> WPP Group) rose 3.1 percent following a reassuring update from French peer Publicis (>> Publicis Groupe), while Compass (>> Compass Group plc), the world's biggest catering firm, jumped more than 5 percent after it raised its expectations for revenue growth.

Their gains however were more than offset by broad-based weakness as markets remained nervous following a sell-off earlier this week triggered by a spike in global yields and volatility.

Miners, along with energy stocks, were a big weight on the FTSE, with the two commodities-related sectors collectively wiping around 40 points off the index, as prices of copper <CMCU3> and other metals fell and oil retreated.

Precious metals miner Randgold (>> Randgold Resources) fell 2.4 percent after HSBC raised its rating on the stock but trimmed its price target. Antofagasta (>> Antofagasta) and BHP Billiton (>> BHP Billiton Plc) were also both down around 2.5 percent.

Among midcaps, Sophos (>> Sophos Ltd) fell 17.5 percent after the cloud services provider reported slower growth in the amount it bills its customers, while TalkTalk (>> TalkTalk Telecom Group) slumped after flagging a dividend cut and a cash call.

(Reporting by Danilo Masoni and Kit Rees; Editing by Peter Graff)

By Danilo Masoni and Kit Rees

Stocks mentioned in the article
ChangeLast1st jan.
ANTOFAGASTA -6.97% 886.4 Delayed Quote.-5.19%
ASTRAZENECA -0.61% 6015 Delayed Quote.18.18%
BARCLAYS -0.29% 183.96 Delayed Quote.-9.16%
BHP BILLITON PLC 0.50% 1701.6 Delayed Quote.11.21%
BRITISH AMERICAN TOBACCO 0.55% 4172 Delayed Quote.-17.32%
COMPASS GROUP PLC -0.48% 1655 Delayed Quote.3.94%
GILEAD SCIENCES 0.44% 77.5 Delayed Quote.7.72%
GLAXOSMITHKLINE 0.59% 1560 Delayed Quote.17.26%
LLOYDS BANKING GROUP -0.65% 60.98 Delayed Quote.-9.81%
PUBLICIS GROUPE -1.49% 54.34 Real-time Quote.-2.63%
RANDGOLD RESOURCES -1.34% 5302 Delayed Quote.-27.48%
RECKITT BENCKISER 0.81% 6842 Delayed Quote.-1.91%
ROYAL BANK OF SCOTLAND GROUP -1.46% 242.2 Delayed Quote.-11.58%
SOPHOS GROUP PLC 0.50% 507.5 Delayed Quote.-11.40%
TALKTALK TELECOM GROUP 2.65% 119.9 Delayed Quote.-23.11%
UNILEVER 0.34% 4384.5 Delayed Quote.5.91%
UNILEVER (NL) 0.73% 49.515 Delayed Quote.4.73%
WPP GROUP -0.81% 1223.5 Delayed Quote.-8.02%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
08/09ASTRAZENECA : Ex-dividend day for interim dividend
08/08Merck's Zepatier price cut lands it co-exclusive status on Express Scripts 20..
08/08ASTRAZENECA : Settles Texas Drug Marketing Litigation -- Bloomberg
08/03Merck, AstraZeneca Get EMA Orphan Designation for Selumetinib
08/03ASTRAZENECA : Selumetinib granted orphan designation in Europe for neurofibromat..
08/03ASTRAZENECA : EMA grants OD for selumetinib in NF1
08/01More drugmakers build Brexit stockpiles as EU agency faces exodus
07/27ASTRAZENECA : Imfinzi receives positive EU CHMP opinion for locally-advanced, un..
07/27ASTRAZENECA : Imfinzi Receives EU Marketing Recommendation
More news
News from SeekingAlpha
10:58aCHECKPOINT THERAPEUTICS : Potential For A Near-Term Run Up 
08:00a3 THINGS IN BIOTECH, AUGUST 14 : Is Stemline Finally A Go In Cancer? 
08/11Eli Lilly Is An Attractive Buy For 2018 
08/09BeiGene launches late-stage study of tislelizumab in first-line lung cancer 
08/08AstraZeneca goes ex-dividend tomorrow 
Financials ($)
Sales 2018 22 224 M
EBIT 2018 5 355 M
Net income 2018 2 201 M
Debt 2018 14 768 M
Yield 2018 3,55%
P/E ratio 2018 41,51
P/E ratio 2019 34,39
EV / Sales 2018 5,11x
EV / Sales 2019 4,81x
Capitalization 98 768 M
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 76,1 $
Spread / Average Target -1,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA18.18%98 768
JOHNSON & JOHNSON-6.42%350 770
PFIZER13.00%239 423
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
MERCK AND COMPANY17.42%175 715